Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ADSs (Dividend Re-investment) |
| Instrument | American Depositary Shares (ISIN: US37733W1053) |
| Transaction Price | $44.19 |
| Volume | 1,191.434 ADSs |
| Transaction Date | July 18, 2016 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine acquisition of shares by an executive following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a factual record of a single transaction.
Investor Verification Points
- Verify the identity of the PDMR: Mr. D E Troy, SVP & General Counsel.
- Confirm the transaction was an acquisition via dividend re-investment, not an open market purchase.
- Note the transaction occurred on July 18, 2016, at a price of $44.19 per ADS.
- Recognize that this filing does not contain quarterly or annual financial results.